Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06741086 Prophylaxis in Severe Hemophilia A or B
NCT03938792Phase 3Completed
- Sponsor
- Pfizer
- Start
- Mar 2020
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 20
01
Overview
A Phase 3 trial of marstacimab in hemophilia A, hemophilia B (HB), sponsored by Pfizer. Started Mar 2020; status: completed.
02
Drugs
marstacimab
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT03938792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03938792.